Table 2

Characteristics of patients after the first and second dose COVID-19 vaccines

CharacteristicsTotal (n=462)First doseSecond doseP value
Vaccination completed, n (%)400 (86.6)
Vaccination received, n (%)
 Sinovac Life251 (54.3)
 Sinopharm BIBP173 (37.5)
 Others38 (8.2)
Side effects after any vaccination*, n (%)141 (30.5)
Gout flare after any vaccination, n (%)203 (43.9)
 Flare ratio, n/N (%)119/203 (58.6)115/203 (56.7)0.65
 VAS, mean (SD)5.02 (2.3)5.65 (2.3)0.04
 Without other specific triggers†, n/N (%)67/119 (56.3)61/115 (53.0)0.70
 Timing of gout flare (days), n/N (%)<0.001
  Within 1 week36/119 (30.3)22/115 (19.1)
  1 week ~1 month63/119 (52.9)48/115 (41.7)
  1~3 months20/119 (16.8)45/115 (39.1)
 Main joint site of gout flare, n/N (%)0.07
  First MTP49/119 (41.2)58/115 (50.4)
  Ankle and heel53/119 (44.5)51/115 (44.4)
  Knee15/119 (12.6)4/115 (3.5)
  Wrist2/119 (1.7)2/115 (1.7)
  • *Side effects after vaccination includes cold symptoms (fatigue, cough, fever, muscle pain nd headache); wheezing or shortness of breath; nausea, vomiting or diarrhoea; flustered and chest tightness.

  • †Other specific triggers include cold, exercise, alcohol consumption, diuretic use and purine intake.

  • VAS, visual analogue score; MTP, metatarsophalangeal.